Hepatic arterial administration of activated leukocytes in patients with liver metastases

Cancer Biotherapy and Radiopharmaceuticals

Volumn 17, Issue 5, 2002, Pages 545-552

  Melichar, Bohuslav ^a   Toušková, Miroslava ^a   Bláha, Milan ^a   Veselý, Pavel ^a   Dvořák, Josef ^a   Krajina, Antonín ^a   Cerman Jr , Jaroslav ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Adoptive immunotherapy; Hepatic arterial infusion; Lymphocytes; Monocytes

Indexed keywords

CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MELPHALAN; RECOMBINANT INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; ADULT; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; COLORECTAL CANCER; CYTOTOXICITY; FEMALE; FLOW CYTOMETRY; HEPATIC ARTERY; HUMAN; HUMAN CELL; KIDNEY CANCER; LEUKAPHERESIS; LEUKOCYTE; LEUKOCYTE ACTIVATION; LIVER METASTASIS; LYMPHOCYTE; MALE; MELANOMA; MONOCYTE; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0036031423     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497802760804772     Document Type: Article

References (27)

1. Willis RA. The Spread of Tumours in the Human Body. Butterworths, London, 1973, pp. 175-183.
2. Patanaphan V, Salazar OM. Colorectal cancer: Metastatic patterns and prognosis. South Med J 1993;86:38-41.
3. Ryan L, Kramar A, Borden E. Prognostic factors in metastatic melanoma. Cancer 1993;71:2995-3005.
4. Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol 1954;30:969-985.
5. August DA. Theoretic and experimental aspects of regional liver infusion. Surg Oncol Clin N Am 1996;5:399-409.
6. Martin JK Jr, O'Connell MJ, Wieand HS, Fitzgibbons RJ Jr, Mailliard JA, Rubin J, Nagorney DM, Tschetter LK, Krook JE. Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. Arch Surg 1990;125:1022-1027.
7. Kemeny N, Daly J, Reichman B, Geller N, Botet J, Oderman P. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. Ann Intern Med 1987;107:459-465.
8. Hohn DC, Stagg RJ, Friedman MA, Hannigan JF, Rayner A, Ignoffo RJ, Acord P, Lewis BJ. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: The Northern California Oncology Group trial. J Clin Oncol 1989;7:1646-1654.
9. Rougier P, Laplanche A, Huguier M, Hay JM, Ollivier JM, Escat J, Salmon R, Julien M, Roullet Audy JC, Gallot D, Gouzi JL, Pailler JL, Elisa D, Lacaine F, Roos S, Rotman N, Luboinski M, Lasser P. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: Long-term results of a prospective randomized trial. J Clin Oncol 1992;10:1112-1118.
10. Chang AE, Schneider PD, Sugarbaker PH, Simpson C, Culnane M, Steinberg SM. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 1987;206:685-693.
11. Earlam S, Glover C, Davies M, Fordy C, Allen-Mersh TG. Effect of regional and systemic fluorinated pyrimidine chemotherapy on quality of life in colorectal liver metastasis patients. J Clin Oncol 1997;15:2022-2029.
12. Meta Analysis Group in Cancer. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 1996;88:252-258.
13. Osband ME, Lavin PT, Babayan RK, Graham S, Lamm DL, Parker B, Sawczuk I, Ross S, Krane RJ. Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma. Lancet 1990;335:994-998.
14. Aruga A, Yamauchi K, Takasaki K, Furukawa T, Hanyu F. Induction of autologous tumor-specific cytotoxic T cells in patients with liver cancer. Characterization and clinical utilization. Int J Cancer 1991;49:19-24.
15. Yeung AW, Pang YK, Tsang YC, Wong SW, Leung JS. Short-duration in vitro interleukin-2-activated mononuclear cells for advanced cancer. Cancer 1993;71:3633-3639.
16. Takayama T, Makuuchi M, Sekine T, Terui S, Shiraiwa H, Kosuge T, Yamazaki S, Hasegawa H, Suzuki K, Yamagata M, Fujii M, Tanaka T, Kakizoe T. Distribution and therapeutic effect of intraarterially transferred tumor-infiltrating lymphocytes in hepatic malignancies, Cancer 1991;68:2391-2396.
17. Fagan EA, Pulley M, Limb A, Wolstencroft R, Cranenburgh C, De Vinci C, Karani J, Michell M, Nunnerley H, Zaman S, Pizza G, Dumonde D, Williams R. Adoptive immunotherapy administered via the hepatic artery and intralesional interleukin-2 in hepatocellular carcinoma. Cancer Treat Rev 1989;16:151-160.
18. Keilholz U, Schlag P, Tilgen W, Brado B, Galm F, Gorich J, Kauffmann GW, Moller P, Schneider S, Hunstein W. Regional administration of lymphokine-activated killer cells can be superior to intravenous application. Cancer 1992;69:2172-2175.
19. Matsuhashi N, Moriyama T, Nakamura I, Ishikawa T, Ohnishi S, Nakagama H, Imawari M, Takaku F. Adoptive immunotherapy of primary and metastatic liver cancer via hepatic artery catheter. Eur J Cancer 1990;26:1106-1107.
20. Hennemann B, Scheibenbogen C, Schuminchen C, Andreesen R. Intrahepatic adoptive immunotherapy with autologous tumor cytotoxic macrophages in patients with cancer. J Immunother 1995;18:19-27.
21. Ferlazzo G, Scisca C, Iemmo R, Cavaliere R, Quartarone G, Adamo V, Frazzetti G, Costa G, Melioli G. Intralesional sonographically guided injections of lymphokine-activated killer cells and recombinant interleukin-2 for the treatment of liver tumors: A pilot study. J Immunother 1997;20:158-163.
22. van de Loosdrecht AA, Nennie E, Ossenkoppele GJ, Beelen RHJ, Langenhuijsen MMAC. Cell mediated cytotoxicity against U937 cells by human monocytes and macrophages in a modified colorimetric MTT assay. J Immunol Methods 1991;141:15-22.
23. Melichar B, Touskova M, Solichova D, Kralickova P, Kopecky O. CD4+ T-lymphocytopenia and systemic immune activation in patients with primary and secondary liver tumours. Scand J Clin Lab Invest 2001;61:363-370.
24. Ratto GB, Zino P, Mirabelli S, Minuti P, Aquillina R, Fantino G, Spessa E, Ponte M, Bruzzi P, Melioli G. A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma. Cancer 1996;78:244-251.
25. Kimura H, Yamaguchi Y. A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. Cancer 1997;80:42-49.
26. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: A randomized trial, Lancet 2000;356:802-807.
27. Hanazaki K, Kawamura N, Sodeyama H, Wakabayashi M, Yokoyama S, Sode Y, Miyazaki T, Okazaki Y, Carcinoembryonic antigen and intra-arterial chemotherapy response of liver metastases. Hepatogastroenterology 1998;45:462-467.